BenzingaSeptember 22, 2026 at 5:07 AM NYLast Month
FDA Grants Jaguar Health Family Company Napo Pharma's Request For Waiver Of Fee Associated With PDUFA For Mytesi For 2027 Fiscal Year
Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and SBS for crofelemer powder for oral solution, targeting an NDA filing
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
